The research team set out to address a persistent gap in nutritional science. While numerous studies in adults have connected ultra-processed food intake with overweight and obesity, robust longitudinal evidence in children and adolescents has remained limited. Most existing pediatric studies rely on short follow-up periods or single measurements, making it difficult to establish whether diet drives weight change or whether body weight shapes dietary behavior. The Dutch researchers designed their analysis to capture the dynamic relationship between diet and growth over the crucial transition from early childhood into adolescence, using repeated measurements of height and weight collected by trained nurses rather than self-reported values.

The study drew on two complementary Dutch cohorts. The first, GECKO Drenthe, is a birth cohort coordinated through the Groningen Expert Center for Kids with Obesity, in which 1,091 children, evenly split between boys and girls, had their diets assessed at age three using a validated food frequency questionnaire completed with parental assistance. The second, Lifelines, is a large population-based cohort in which 2,970 children aged eight to twelve, half of them male, provided dietary information through the same validated instrument. In both cohorts, food items were categorized according to the NOVA classification system, the most widely used framework for distinguishing ultra-processed products, which are industrial formulations typically made from refined substances and additives with little resemblance to whole foods.

The scale of ultra-processed food consumption among these Dutch children was striking. In the GECKO cohort, the median intake at age three was 744 grams per day, accounting for roughly 52 percent of total food intake by weight. In Lifelines, children aged eight to twelve consumed a median of 908 grams per day, representing about half of everything they ate. These figures mean that the average Dutch child in these cohorts obtained the majority of their daily food, by weight, from industrially manufactured products, a pattern consistent with broader trends across high-income countries where ultra-processed items dominate children’s diets.

The central finding emerged from the younger cohort. In GECKO Drenthe, children in the highest quartile of ultra-processed food consumption at age three showed a significantly greater increase in their age- and sex-standardized body mass index, known as BMI z-score, between age three and age ten or eleven compared with children in the lowest quartile. The regression coefficient was 0.22, with a 95 percent confidence interval of 0.07 to 0.37, indicating a statistically robust association. BMI z-scores are a standard pediatric metric that expresses a child’s body mass index relative to peers of the same age and sex, allowing researchers to track whether a child’s weight trajectory is drifting upward relative to the population norm over time.

Perhaps the most intriguing result, however, came from the cross-lagged panel models, a statistical technique designed to probe the temporal direction of relationships between variables measured at multiple time points. In the GECKO cohort, these analyses indicated a directional association in which early ultra-processed food intake predicted later BMI z-score, rather than the reverse. This is a critical distinction in observational nutrition research, because heavier children are sometimes assumed to simply eat more of everything, including processed products. The cross-lagged evidence suggests that, at least in early childhood, the arrow of causality points from diet to weight, with high ultra-processed food consumption preceding and predicting subsequent weight gain rather than resulting from it.

The picture in older children was more complicated. In the Lifelines cohort, higher ultra-processed food intake at ages eight to twelve was actually associated with lower BMI z-scores measured between ages nine and seventeen. Compared with children in the lowest consumption quartile, those in the second quartile had a coefficient of minus 0.12, those in the third quartile minus 0.20, and those in the highest quartile minus 0.13, all with confidence intervals excluding zero. The authors themselves characterize this inverse association as less consistent, and they caution against interpreting it as evidence that ultra-processed foods protect against weight gain in adolescence. Reverse causation, residual confounding by socioeconomic status or physical activity, and the coarser dietary assessment possible in older children may all contribute to the unexpected pattern.

Several biological and behavioral mechanisms could explain why early childhood appears especially vulnerable to the effects of ultra-processed foods. During the first years of life, the body undergoes rapid growth and metabolic programming, and adiposity trajectories established in this period tend to track into later childhood and adulthood. Ultra-processed products are typically energy-dense, high in added sugars, refined starches and unhealthy fats, and low in fiber and micronutrients, a combination that can promote passive overconsumption because they are palatable, convenient and often marketed in large portions. Early exposure may also shape taste preferences and eating behaviors that persist for years, embedding a dietary pattern that continuously favors excess energy intake. The developing hypothalamic regulation of appetite and satiety may likewise be influenced by the nutrient profile of the early diet, though the authors emphasize that further longitudinal research across developmental stages is needed to confirm these pathways.

The study’s strengths lie in its prospective design, its use of two independent cohorts, objectively measured height and weight collected by trained nurses, and a validated food frequency questionnaire applied consistently across age groups. Standardized BMI z-scores and the International Obesity Task Force criteria for overweight and obesity provided internationally comparable endpoints. Nevertheless, the researchers acknowledge limitations inherent to observational nutrition studies. Food frequency questionnaires depend on parental reporting for young children and self-report for older ones, both of which are subject to measurement error and social desirability bias. The NOVA classification, while influential, groups heterogeneous products together, and residual confounding by family socioeconomic circumstances, physical activity and other dietary components cannot be fully excluded. The inverse association observed in Lifelines in particular underscores the need for caution before drawing firm conclusions about adolescents.

The implications for public health are nonetheless significant. If early childhood is indeed a sensitive period for the obesogenic effects of ultra-processed foods, interventions aimed at reducing these products in toddler and preschool diets could yield disproportionate long-term benefits, potentially preventing the upward drift in body mass index that foreshadows adolescent and adult obesity. The findings add momentum to international efforts, including front-of-pack labeling schemes, marketing restrictions targeting young children and dietary guidelines that explicitly recommend limiting ultra-processed products. As ultra-processed foods continue to expand into low- and middle-income countries, understanding which developmental windows matter most will be essential for designing effective prevention strategies. This Dutch study provides some of the strongest longitudinal evidence yet that the earliest years of life may be exactly when dietary quality matters most for lifelong weight trajectories.

Subject of Research: Longitudinal associations between ultra-processed food consumption and body mass index development from childhood to adolescence

Article Title: Ultra-processed food consumption and body mass index development from childhood to adolescence in Dutch cohorts

Article References: Yang, J., Navis, G., & Corpeleijn, E. (2026). Ultra-processed food consumption and body mass index development from childhood to adolescence in Dutch cohorts. BMC Medicine. https://doi.org/10.1186/s12916-026-05270-4

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05270-4

Keywords: ultra-processed foods, childhood obesity, BMI z-score, NOVA classification, GECKO Drenthe cohort, Lifelines cohort, pediatric nutrition, longitudinal study, weight gain, cross-lagged analysis, public health, Netherlands

The research team, led by Jingwei Tian and Yaokai Chen of Chongqing Public Health Medical Center together with collaborators at Zunyi Medical University and other Chinese institutions, followed 2,379 virologically suppressed people living with HIV for 144 weeks, nearly three years. All participants began the observation period on a classic first-line combination: tenofovir disoproxil fumarate plus lamivudine plus efavirenz, abbreviated TDF/3TC/EFV. This regimen served Chinese treatment programs for years, but it carries well-documented drawbacks, including kidney and bone toxicity from tenofovir disoproxil fumarate and central nervous system side effects from efavirenz. Some patients in the cohort continued on this older combination, while others switched to one of two modern alternatives: the single-tablet regimen bictegravir/emtricitabine/tenofovir alafenamide, known as BIC/FTC/TAF, or the two-drug combination dolutegravir plus lamivudine, known as DTG/3TC.

Because patients were not randomly assigned to their treatment paths, the investigators faced the fundamental challenge of any observational study: people who switch medications often differ systematically from those who do not. To address this, the team applied propensity score overlap weighting, a statistical technique that reweights the comparison groups so that baseline characteristics such as age, sex, body measurements, and laboratory values are balanced across them. This approach allows the analysis to approximate, though never perfectly replicate, the conditions of a randomized trial. The primary endpoint was the longitudinal change in body weight and body mass index from baseline to weeks 24, 48, 96, and 144. Secondary endpoints captured a broader metabolic picture, including changes in blood lipids, fasting blood glucose, the triglyceride-glucose index known as TyG, and serum uric acid.

The headline finding was unambiguous: weight and body mass index increased in every group over the 144 weeks, but the gains were markedly larger among those who switched to INSTI-based regimens. Patients moving to BIC/FTC/TAF gained more weight than those moving to DTG/3TC at weeks 24, 48, and 144, with the bictegravir-based regimen showing the steepest trajectory. This pattern echoes signals from international trials and cohort studies that have linked INSTI initiation and switching to clinically meaningful weight gain, but the Chinese data are particularly valuable because most prior evidence came from North American, European, and African populations, where baseline body composition and dietary patterns differ considerably.

The lipid results revealed a more nuanced picture. Compared with patients who stayed on TDF/3TC/EFV, both switch groups experienced increases in total cholesterol and low-density lipoprotein cholesterol, the fraction commonly labeled bad cholesterol because of its association with atherosclerotic cardiovascular disease. However, high-density lipoprotein cholesterol, the protective fraction, declined only in the BIC/FTC/TAF group, while triglycerides remained stable among those taking DTG/3TC. The direction of these changes matters clinically: a rise in LDL-C paired with a fall in HDL-C, as seen with bictegravir-based switching, shifts the lipid profile in a direction generally considered atherogenic, whereas the dolutegravir two-drug regimen appeared metabolically gentler on this front.

Beyond weight and lipids, the study tracked two additional metabolic markers that are gaining attention in HIV care. Fasting blood glucose rose in both switch groups, and serum uric acid also climbed in both, with significantly larger uric acid increases among patients on BIC/FTC/TAF. Elevated uric acid is the biochemical hallmark of hyperuricemia, the precursor state for gout, and has emerged as a recurrent finding in INSTI pharmacovigilance. The triglyceride-glucose index, a simple surrogate for insulin resistance calculated from fasting triglycerides and glucose, provided a window into early metabolic dysfunction without requiring formal glucose tolerance testing.

When the researchers translated these continuous laboratory changes into clinical diagnoses using multivariable Cox proportional hazards models, the differences between the two switch strategies became striking. Patients who switched to BIC/FTC/TAF faced more than double the hazard of developing overweight or obesity compared with those continuing the older regimen, with an adjusted hazard ratio of 2.47 and a 95 percent confidence interval of 1.96 to 3.10. They also carried a modestly elevated risk of dyslipidemia, at an adjusted hazard ratio of 1.18, and a substantially increased risk of hyperuricemia, at 2.23. The DTG/3TC group also fared worse than those who stayed on TDF/3TC/EFV, with adjusted hazard ratios of 1.56 for overweight or obesity and 1.76 for hyperuricemia, but the magnitude of risk was consistently lower than for the bictegravir-based triple-drug regimen. Notably, neither switch strategy significantly changed the risk of developing type 2 diabetes over the follow-up period.

The mechanistic story behind these observations remains incomplete, but several hypotheses circulate in the field. Integrase inhibitors may influence adipocyte biology and appetite regulation, potentially through effects on melanocortin signaling pathways, while the reversal of efavirenz-related toxicity could unmask baseline metabolic differences. Tenofovir alafenamide, the prodrug used in the BIC/FTC/TAF regimen, achieves high intracellular concentrations with lower plasma tenofovir exposure, sparing kidneys and bones, but some studies suggest it contributes more to weight gain than the older disoproxil fumarate salt. The uric acid signal may reflect changes in renal tubular handling as patients transition away from tenofovir disoproxil fumarate, which has mild uricosuric properties that lower serum urate. Disentangling drug-specific effects from the metabolic recovery that follows viral suppression and from the removal of older drugs remains one of the central analytical challenges in this literature.

For clinicians, the study’s practical message is one of vigilance rather than alarm. The authors emphasize that switching from TDF/3TC/EFV to either INSTI regimen was associated with significant increases in body weight and selected lipid parameters, and that BIC/FTC/TAF displayed a more pronounced adverse metabolic profile than DTG/3TC. They argue that metabolic monitoring after any switch to INSTI-based therapy deserves routine incorporation into HIV care, with particular attention for patients moving to bictegravir-based regimens. This is especially relevant in China and other Asian settings, where populations may have different baseline metabolic risk profiles and where the threshold at which weight gain becomes clinically consequential may differ from Western populations.

The study’s retrospective design imposes limits that the authors and the broader field acknowledge. Overlap weighting balances measured confounders but cannot account for unmeasured variables such as diet, physical activity, or the clinical reasons that prompted a switch in the first place. The 144-week horizon, while long by observational standards, may still underrepresent the cumulative metabolic burden of decades on therapy. Nevertheless, with 2,379 participants and nearly three years of longitudinal laboratory data, the analysis offers one of the clearest head-to-head real-world comparisons of these two widely used switch strategies in an Asian population. As INSTI regimens continue to displace older combinations globally, findings like these will shape how clinicians weigh the undeniable tolerability and convenience advantages of modern therapy against a metabolic cost that is now difficult to ignore.

Subject of Research: Long-term metabolic effects of switching from TDF/3TC/EFV to INSTI-based antiretroviral regimens in people living with HIV

Article Title: Long-term metabolic changes after switching from TDF/3TC/EFV to BIC/FTC/TAF or DTG/3TC in people living with HIV: a retrospective comparative cohort study in China

Article References: Tian, J., Zhou, Y., Qin, Y., Lu, Y., Wang, Q., Liu, P., Kong, F., Harypursat, V., & Chen, Y. (2026). Long-term metabolic changes after switching from TDF/3TC/EFV to BIC/FTC/TAF or DTG/3TC in people living with HIV: a retrospective comparative cohort study in China. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14425-w

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14425-w

Keywords: HIV, antiretroviral therapy, bictegravir, dolutegravir, tenofovir alafenamide, weight gain, dyslipidemia, hyperuricemia, integrase inhibitors, metabolic syndrome, cohort study, China

The review, led by Lotte M.G. Hulskotte and colleagues in the Netherlands, systematically searched PubMed and Embase for evidence on drug–drug and food–drug interactions and pharmacodynamic adverse effects of all thirty SMIs approved by the US Food and Drug Administration and the European Medicines Agency for non-small cell lung cancer, from long-standing agents such as erlotinib and crizotinib to newcomers including zongertinib, sevabertinib and sunvozertinib. The searches, initiated in October 2025 and finalised in July 2026, were supplemented with regulatory documents from both agencies, and the authors applied a pragmatic hierarchy of evidence ranking pharmacokinetic studies and meta-analyses above phase 1/2 trials, observational data, label information and expert opinion.

At the heart of the pharmacokinetic problem lies chemistry. Most SMIs are weakly basic, lipophilic molecules whose absorption depends delicately on the acidity of the stomach. When acid-reducing agents such as proton pump inhibitors raise gastric pH, the drugs shift toward a less soluble, non-ionised form that dissolves poorly, cutting systemic exposure. The magnitude is striking: selpercatinib exposure fell by roughly 70 percent when omeprazole was given in the fasted state, and sotorasib lost 57 percent of its exposure with omeprazole even when taken with food. Erlotinib, co-administered with esomeprazole, lost nearly half its area under the curve. Bioequivalence standards allow exposure to vary only within 80 to 125 percent of the reference value, so deviations of this size translate directly into subtherapeutic concentrations, lost efficacy and, ultimately, disease progression.

Liver enzymes provide the second major axis of interaction. Most SMIs are metabolised primarily by cytochrome P450 iso-enzymes, above all CYP3A, so potent inducers such as rifampicin can collapse drug levels while inhibitors such as itraconazole can push them to toxic heights. Rifampicin cut adagrasib exposure by 95 percent, while itraconazole raised repotrectinib exposure nearly sevenfold. Compounding the problem, several agents are themselves auto-inducers or auto-inhibitors of CYP enzymes — dabrafenib, encorafenib, lorlatinib and osimertinib induce their own clearance, while adagrasib, ceritinib and taletrectinib inhibit it — meaning that single-dose interaction studies may not predict steady-state behaviour. Transporters such as P-glycoprotein and breast cancer resistance protein add further complexity, although their intestinal contribution is generally considered minor.

Food, by contrast, can be an ally. High-fat meals delay gastric emptying, increase bile flow and create a lipophilic environment that enhances solubilisation of many of these drugs. Alectinib is the poster child: a high-fat meal raised its systemic exposure by roughly 230 to 250 percent, and a clinical crossover study showed that 35 percent of patients failed to reach the alectinib exposure threshold when taking the drug with low-fat yoghurt, compared with only 5 percent eating a continental breakfast or lunch. This very property has been exploited therapeutically — ceritinib’s approved dose fell from 750 mg fasted to 450 mg with food after feeding studies showed comparable exposure with less gastrointestinal toxicity, and the FDA has required a post-marketing evaluation of taletrectinib dosing with food for the same reason. Food also reduced inter-individual variability for several agents, improving predictability of therapeutic exposure.

The interplay between food and acid suppression, however, is drug-specific and sometimes counterintuitive. Selpercatinib’s PPI-induced exposure loss is largely rescued by co-administration with a meal. Sotorasib behaves in the opposite way, losing even more exposure when food and a PPI are combined. For erlotinib, an acidic glass of cola partially reversed the damage done by esomeprazole, restoring roughly 40 percent of lost exposure. The authors conclude that when PPI use is unavoidable, clinicians should weigh the individual pharmacokinetics of each SMI, considering food co-administration, acidic beverages or staggered dosing as mitigation strategies.

Turning to the drugs’ intrinsic toxicities, the review paints a landscape where class effects mask considerable agent-to-agent variation. Corrected QT interval prolongation, which can degenerate into dangerous arrhythmias, affects the entire class but is most pronounced with adagrasib, ceritinib, crizotinib, encorafenib, osimertinib and taletrectinib, with median increases exceeding ten milliseconds and the highest rates of clinically significant prolongation seen with adagrasib, encorafenib, taletrectinib, entrectinib and selpercatinib. Because the effect is largely exposure-dependent, any interaction that raises drug levels also raises arrhythmia risk. Others, including alectinib, gefitinib, capmatinib and the newer HER2 inhibitors, showed no clinically meaningful QTc changes. Management centres on electrocardiographic monitoring, correction of concomitant QT-prolonging factors, and dose interruption or discontinuation when the QTc exceeds 500 milliseconds.

Pneumonitis, the non-infectious inflammation of lung tissue that can prove fatal, occurs with most SMIs but clusters around particular agents. Brigatinib carried the highest trial incidence at 9 percent of all-grade events, with an unusual early onset within the first week — the rationale for its mandatory one-week 90 mg lead-in dose before escalation. Pralsetinib affected about 12 percent of patients including one fatal case, while adagrasib, capmatinib, ensartinib and sunvozertinib each produced events in 5 to 6 percent. Strikingly, ethnicity emerged as an independent risk factor: all-grade interstitial lung disease was reported in up to 15 percent of Japanese patients on gefitinib and 17 percent on osimertinib. Rechallenge after pneumonitis remains fraught — one real-world study found a 50 percent twelve-month recurrence rate when patients were rechallenged with osimertinib itself, versus 15 percent with alternative EGFR inhibitors.

Among the quieter but increasingly recognised toxicities is weight gain. NTRK inhibitors cause weight gain in 53 percent of patients, likely through on-target inhibition of TRKB, a hypothalamic receptor governing appetite, with entrectinib reaching roughly 66 percent incidence. Among ALK inhibitors, lorlatinib produced all-grade weight gain in up to 81 percent of patients, with grade 3 events in up to 23 percent and a median gain of 4.5 kilograms in a prospective study; alectinib added an average 9 centimetres of waist circumference over a year. The irony is acute for alectinib, whose absorption depends on high-fat meals. Management spans lifestyle counselling, systematic weight monitoring and, where needed, GLP-1 receptor agonists — though even here caution is warranted, as semaglutide was recently shown to reduce alectinib exposure by 32 percent.

Further distinguishing the class, EGFR inhibitors uniquely damage the ocular surface — keratitis in 1 to 3 percent of patients and conjunctivitis up to 24 percent with dacomitinib — because EGFR sustains corneal epithelium and tear production, while BRAF/MEK combinations bring uveitis and retinal pigment epithelial detachment, the latter affecting roughly 30 percent of patients on encorafenib plus binimetinib. Central neurotoxicity, including cognitive disorders in up to a third of patients on capmatinib, entrectinib, lorlatinib and repotrectinib, peripheral neuropathy in up to 44 percent on lorlatinib, dabrafenib-driven pyrexia in 39 percent of combination-treated patients, severe stomatitis with second-generation EGFR inhibitors, and hepatotoxicity necessitating intra-class switches — erlotinib after gefitinib injury, adagrasib after sotorasib injury — complete the picture. The authors’ overarching message is that safe prescribing of these transformative drugs demands equal attention to what patients eat, what else they swallow, and which specific molecule sits in the capsule: pharmacokinetic–pharmacodynamic associations remain under-studied, and filling that gap could enable personalised dosing that maximises efficacy while sparing patients avoidable harm.

Subject of Research: Pharmacokinetic and pharmacodynamic considerations for prescribing small molecule kinase inhibitors in non-small cell lung cancer

Article Title: Pharmacological considerations for prescribing of small molecule inhibitors in patients with non-small cell lung cancer

Article References: Hulskotte, L. M., Veerman, G. M., Lanser, D. A., Reyners, A. K., van Schaik, R. H., Dingemans, A.-M. C., Taxis, K., Mathijssen, R. H., & Jansman, F. G. (2026). Pharmacological considerations for prescribing of small molecule inhibitors in patients with non-small cell lung cancer. eClinicalMedicine, 100, Article 104199. https://doi.org/10.1016/j.eclinm.2026.104199

Image Credits: AI Generated

DOI: 10.1016/j.eclinm.2026.104199

Keywords: non-small cell lung cancer, small molecule inhibitors, drug-drug interactions, pharmacokinetics, CYP3A, proton pump inhibitors, food-drug interactions, QTc prolongation, pneumonitis, weight gain, ocular toxicity, targeted therapy

The study, conducted at the University Medical Center Ho Chi Minh City and published in Discover Mental Health, followed patients who were either initiating or continuing antidepressant therapy. Participants were assessed at four time points: baseline, one month, three months, and six months. Depressive symptoms were measured with the Quick Inventory of Depressive Symptomatology–Self-Report, a sixteen-item instrument widely used in clinical research, while eating attitudes and behaviors were tracked using the Eating Attitudes Test-26, a validated screening tool that captures dieting behavior, food preoccupation, and oral control.

At the start of the study, the clinical picture was severe. More than 32 percent of participants scored above 15 on the QIDS-SR16, indicating severe or very severe depression. This is consistent with the reality that many patients reach psychiatric care only after symptoms have become disabling. Major depressive disorder has long been linked to disturbances in appetite and weight, with some patients losing interest in food entirely and others turning to eating as a coping mechanism. What has remained underexplored, the authors note, is how these psychological attitudes toward eating evolve once treatment begins and mood begins to stabilize.

The trajectory of depression over the six months was, by every standard metric, a success story. By the end of follow-up, 45.2 percent of participants had achieved remission, meaning their depressive symptoms had receded to clinically insignificant levels. For a condition that resists treatment in a large fraction of patients, this remission rate represents meaningful therapeutic progress and underscores the effectiveness of pharmacological care delivered in a structured outpatient setting.

The eating data told a strikingly different story. The mean EAT-26 total score rose from 4.7 at baseline to 17.0 at six months, a mean increase of 12.3 points that was highly statistically significant. All three subscales of the instrument—Dieting, Bulimia and Food Preoccupation, and Oral Control—showed significant progressive increases over the same period. Perhaps most alarming from a screening standpoint, the proportion of patients crossing the conventional clinical threshold of an EAT-26 score of 20 or higher grew from just 1.6 percent at baseline to 39.6 percent at six months. In other words, roughly two in five patients who began treatment with unremarkable eating attitudes ended the study period scoring in a range typically associated with elevated risk of disordered eating.

To understand what was driving this shift, the researchers turned to generalized structural equation modeling, a statistical framework capable of handling multivariate longitudinal associations while accounting for the complexity of repeated measurements. Two factors emerged with particular force. Patients who reported increased appetite or weight gain during treatment scored substantially higher on the EAT-26, with a beta coefficient of 3.2, while those who achieved clinical remission of their depression scored significantly lower, with a beta of minus 6.1. Both associations were highly significant, and together they sketch a nuanced picture: recovery itself appears protective, but the metabolic and appetite side effects that often accompany antidepressant medications may push patients toward dieting behaviors, food preoccupation, and restrictive attitudes even as their mood improves.

This finding carries particular weight given the pharmacology of modern antidepressants. Selective serotonin reuptake inhibitors, serotonin–norepinephrine reuptake inhibitors, and noradrenergic and specific serotonergic antidepressants all interact with neural circuits that regulate both mood and appetite. Some agents are well known to stimulate appetite and promote weight gain, effects that patients frequently report as distressing. The new study suggests these physical changes are not merely cosmetic concerns but may translate into measurable psychological distress centered on food, body, and control, even in patients whose depression is otherwise responding well to treatment.

The authors argue that the divergence between mood improvement and worsening eating attitudes exposes a blind spot in routine psychiatric monitoring. Clinical follow-up for depression typically focuses on mood, sleep, energy, and suicidal ideation, while eating attitudes are rarely assessed unless a patient volunteers concerns. Because the conventional EAT-26 cutoff of 20 would have flagged only the extreme end of the distribution, the researchers emphasize that continuous measures, rather than binary clinical thresholds, are essential for detecting the gradual erosion of healthy eating attitudes that their data reveal. A patient scoring 17 would escape screening under current practice, yet sits within a population whose mean scores more than tripled over six months.

The study’s setting adds an important dimension to its significance. Research on eating psychopathology in depression has been concentrated in high-income Western countries, and data from Southeast Asian populations remain scarce. Cultural factors shape both the expression of depression and attitudes toward food, body size, and dieting, and treatment guidelines imported from other contexts may not transfer cleanly. By demonstrating that the mood-eating divergence emerges in a Vietnamese outpatient cohort, the study suggests the phenomenon is not an artifact of Western clinical populations but a potentially general feature of antidepressant treatment that deserves attention across diverse health systems.

For clinicians, the practical message is straightforward: recovery from depression should be monitored with a wider lens. Patients whose mood is improving but who report new appetite changes, weight gain, or growing preoccupation with food and dieting may be developing disordered eating attitudes that warrant intervention before they harden into clinical eating disorders. For researchers, the findings open a clear agenda for future work, including studies that disentangle the effects of specific antidepressant classes, examine whether the trajectory reverses with longer follow-up, and test whether structured nutritional and psychological support during treatment can prevent the rise in disordered eating attitudes. What this study makes unmistakably clear is that healing the mind and healing the relationship with food are not always the same journey, and that treating depression successfully means watching both.

Subject of Research: Longitudinal changes in disordered eating attitudes and behaviors during antidepressant treatment for major depressive disorder

Article Title: Changes in depressive symptoms and disordered eating attitudes and behaviors during antidepressant treatment among Vietnamese patients with major depressive disorder

Article References: Bui, M. X., Ngo, L. T., Huynh, N., Le, P. T. V., Vuu, L. T. M., Nguyen, N. T. Y., & Nguyen, P. D. (2026). Changes in depressive symptoms and disordered eating attitudes and behaviors during antidepressant treatment among Vietnamese patients with major depressive disorder. Discover Mental Health. https://doi.org/10.1007/s44192-026-00598-y

Image Credits: AI Generated

DOI: 10.1007/s44192-026-00598-y

Keywords: major depressive disorder, antidepressants, disordered eating, EAT-26, QIDS-SR16, appetite changes, weight gain, Vietnam, longitudinal study, psychiatry, mental health, remission